H-CMF                                                ovarian(116)
 _________________________________________________________________
  hexamethylmelami 150 mg/day orally from day 1 to day 14.
  cytoxan......... 150 mg/day orally from day 1 to day 14.
  methotrexate.... 40 mg/sqm IV on day 1 and day 8.
  fluorouracil.... 600 mg/sqm IV on day 1 and day 8.
  FREQUENCY....... Repeat cycle every 28 days.

  reference...
    Young RC.  Chabner BA.  Hubbard SP.  Fisher RI.  Bender RA. 
    Anderson T.  Simon RM.  Canellos GP.  DeVita VT Jr. Advanced 
    ovarian adenocarcinoma. A prospective clinical trial of 
    melphalan (L-PAM) versus combination chemotherapy. New England 
    Journal of Medicine.  299(23):1261-6, 1978 Dec 7. 
  abstract...
    Eighty patients with advanced ovarian adenocarcinoma were 
    treated in a prospective, randomized trial comparing a 
    four-drug combination--hexamethylmelamine, cyclophosphamide, 
    methotrexate and 5-fluorouracil--with the oral alkylating 
    agent, melphalan. Treatment with the four-drug combination was 
    associated with a significantly increased overall response 
    rate (75 vs. 54 per cent) (P less than 0.05), more complete 
    remissions (33 vs. 16 per cent) and longer median survival (29 
    vs. 17 months) (P less than 0.02) but more severe toxicity 
    than occurred with melphalan. Patients with minimal residual 
    disease had a significantly higher overall response rate than 
    patients with extensive residual disease (84 vs. 53 per cent) 
    (P less than 0.05). Patients with advanced disease who 
    achieved a complete remission documented by peritoneoscopy or 
    laparotomy (or both) have a median survival that will exceed 
    three years. The four-drug regimen is more effective than 
    melphalan in the management of advanced ovarian 
    adenocarcinoma.